Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded the Ovarian cancer topic and a MedlinePlus Genetics related topic, and updated the revision from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check10 days agoChange DetectedOvarian cancer and the MedlinePlus Genetics related topic were removed from the page's related topics.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 removed; this is a minor UI revision with no impact on study content, eligibility, enrollment, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision: v3.4.1 is now shown, replacing v3.4.0. No study content or eligibility criteria appear to be changed.SummaryDifference0.0%

- Check39 days agoChange DetectedThe changes add a Show glossary option and standardize metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while removing older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These updates do not alter core study content, eligibility, or results, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check46 days agoChange DetectedAdded related topics: Ovarian cancer and MedlinePlus Genetics to the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.